Quarter Comparison
Revenue
Operating Income
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 atto-ex99_1.htm EX-99.1 EX-99.1 Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 20
EX-99.1 2 atto-ex99_1.htm EX-99.1 EX-99.1 Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of ATTO-1310 in chronic pruritus of unknown origin and high-itch AD planned for 1H 2027 Phase 1 initiation for ATTO-2306 and ATTO-1091 planned in 1H 2027 Upsized Initial Public Offering (IPO) gross proceeds of $332.4 million helps extend cash runway into 2030 SAN CARLOS, Calif., September 2, 2026 – Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today reported financial results for the second quarter ended June 30, 2...
Source
Exhibit EX-99.1
0001193125-26-380215
Filed September 2, 2026 at 8:17 PM UTC. The figures above are from the audited statements, not from this release.